philipn / Dipyridamole for COVID-19 961064be367c8fb02cd5662df5f81ac78cfe8e55

Create Draft
Info from Dr. Yogen Kanthi

Linked https://stm.sciencemag.org/content/12/570/eabd3876, a paper on prothrombotic autoantibodies in COVID-19. Added CC-licensed photo from their paper.

Review changes View this version of the page
You can also use the and keys
Deletions are marked like this Additions are marked like this
The chemical structure of dipyridamole.

Dipyridamole, a vasodilator and antiplatelet drug, has been proposed as a possible COVID-19 therapeutic.

Mechanism of potential benefit

Dipyridamole is said to "[have the] potential to inhibit multiple processes that have been recently linked to COVID-19 severity," such as purinergic signaling (related to inflammation and thrombosis), and may help induction of type 1 IFNs.

Dipyridamole has also been shown to have direct anti-viral effects against SARS-CoV-2, showing anti-SARS-CoV-2 activity in vitro in Vero cells. Dipyridamole's anti-SARS-CoV-2 activity may occur via binding to the SARS-CoV-2 protease Mpro (see Fig. 1B).

Research overviews:

Clinical trials

A list of clinical trials of dipyridamole for COVID-19:

Trial results:

A proof-of-concept trial of 31 COVID-19 patients was carried out in China in early 2020, finding signs of potential benefit.

See also
Dipyridamole was shown to block neutrophil activation by autoantibodies found in serum from patients hospitalized with COVID-19 (Supp Fig 8) Photo CC-BY Yu Zou, et al.
The chemical structure of dipyridamole.

Dipyridamole, a vasodilator and antiplatelet drug, has been proposed as a possible COVID-19 therapeutic.

Mechanism of potential benefit

Dipyridamole is said to "[have the] potential to inhibit multiple processes that have been recently linked to COVID-19 severity," such as purinergic signaling (related to inflammation and thrombosis), and may help induction of type 1 IFNs.

Dipyridamole has also been shown to have direct anti-viral effects against SARS-CoV-2, showing anti-SARS-CoV-2 activity in vitro in Vero cells. Dipyridamole's anti-SARS-CoV-2 activity may occur via binding to the SARS-CoV-2 protease Mpro (see Fig. 1B).

Research overviews:

Clinical trials

A list of clinical trials of dipyridamole for COVID-19:

Trial results:

A proof-of-concept trial of 31 COVID-19 patients was carried out in China in early 2020, finding signs of potential benefit.

See also
Create Draft
Contributed by
Except where otherwise noted, text content is licensed under a Creative Commons Attribution-ShareAlike License. See copyright information.